Literature DB >> 24005809

Overexpression of UHRF1 is significantly associated with poor prognosis in laryngeal squamous cell carcinoma.

Jing-Ting Pi1, Ye Lin, Qiu Quan, Li-Li Chen, Li-Zhu Jiang, Wang Chi, Hong-Yan Chen.   

Abstract

The ubiquitin-like with PHD and ring finger domains 1 (UHRF1) has been reported to be essential for cell proliferation and plays a critical role in the development and progression of many human carcinomas. However, its clinical and prognostic significance in laryngeal squamous cell carcinoma (LSCC) remains unclear. In the current study, 60 patients with LSCC were studied. UHRF1 expression at mRNA and protein levels was detected by quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) and immunohistochemistry, respectively, in both tissues of LSCC and corresponding adjacent normal larynx tissues. Statistical analyses were conducted to test the correlations between UHRF1 expression, clinicopathological parameters, and prognosis. qRT-PCR showed that the expression of UHRF1 mRNA in LSCC tissues was significantly higher than that in adjacent normal larynx tissues (P < 0.001). By immunohistochemistry, overexpression of UHRF1 protein was found in 78.3% (47/60) of the LSCC tissues, while there was negative expression in adjacent normal larynx tissues. Furthermore, increased expression of UHRF1 had remarkably positive relationships with smoking (P < 0.001), advanced T stage (P = 0.005) and clinical stage (P = 0.044), poor histological differentiation (P = 0.048), while there was no correlations between UHRF1, and sex, age and lymph node metastasis (P > 0.05). Overexpression of UHRF1 was also associated with worse overall survival examined by Kaplan-Meier method (P = 0.036). Multivariate analysis showed that increased expression of UHRF1 was an independent prognostic factor for LSCC (P = 0.013). Therefore, overexpression of UHRF1 may play an important role in the development and progression of LSCC, and UHRF1 might be a useful biomarker for the prognosis of LSCC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24005809     DOI: 10.1007/s12032-013-0613-9

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  23 in total

1.  [Incidence and mortality of larynx cancer in China during 2003-2007].

Authors:  Ling-bin Du; Wei-min Mao; Wan-qing Chen; Si-wei Zhang; Chuan-ding Yu; Rong-shou Zheng; Qing-min Xia; Xiang-hui Wang
Journal:  Zhonghua Liu Xing Bing Xue Za Zhi       Date:  2012-04

2.  UHRF1 promotes cell growth and metastasis through repression of p16(ink⁴a) in colorectal cancer.

Authors:  Feng Wang; Yong-Zhi Yang; Chen-Zhang Shi; Peng Zhang; Mary Pat Moyer; Hui-Zhen Zhang; Yang Zou; Huan-Long Qin
Journal:  Ann Surg Oncol       Date:  2012-01-05       Impact factor: 5.344

3.  UHRF1-mediated tumor suppressor gene inactivation in nonsmall cell lung cancer.

Authors:  Alexandros Daskalos; Urszula Oleksiewicz; Anastasia Filia; George Nikolaidis; George Xinarianos; John R Gosney; Angeliki Malliri; John K Field; Triantafillos Liloglou
Journal:  Cancer       Date:  2010-11-08       Impact factor: 6.860

4.  Critical role of the ubiquitin ligase activity of UHRF1, a nuclear RING finger protein, in tumor cell growth.

Authors:  Yonchu Jenkins; Vadim Markovtsov; Wayne Lang; Poonam Sharma; Denise Pearsall; Justin Warner; Christian Franci; Betty Huang; Jianing Huang; George C Yam; Joseph P Vistan; Erlina Pali; Jorge Vialard; Michel Janicot; James B Lorens; Donald G Payan; Yasumichi Hitoshi
Journal:  Mol Biol Cell       Date:  2005-09-29       Impact factor: 4.138

5.  The SRA protein UHRF1 promotes epigenetic crosstalks and is involved in prostate cancer progression.

Authors:  F Babbio; C Pistore; L Curti; I Castiglioni; P Kunderfranco; L Brino; P Oudet; R Seiler; G N Thalman; E Roggero; M Sarti; S Pinton; M Mello-Grand; G Chiorino; C V Catapano; G M Carbone; I M Bonapace
Journal:  Oncogene       Date:  2012-02-13       Impact factor: 9.867

6.  Cell cycle and/or proliferation markers: what is the best method to discriminate cervical high-grade lesions?

Authors:  Marianne Lorenzato; Stephanie Caudroy; Christian Bronner; Ghislaine Evrard; Maryline Simon; Anne Durlach; Philippe Birembaut; Christine Clavel
Journal:  Hum Pathol       Date:  2005-10       Impact factor: 3.466

7.  UHRF1 is a novel molecular marker for diagnosis and the prognosis of bladder cancer.

Authors:  M Unoki; J D Kelly; D E Neal; B A J Ponder; Y Nakamura; R Hamamoto
Journal:  Br J Cancer       Date:  2009-06-02       Impact factor: 7.640

8.  UHRF1 is associated with epigenetic silencing of BRCA1 in sporadic breast cancer.

Authors:  Wei Jin; Li Chen; Ying Chen; Si-Guang Xu; Gen-Hong Di; Wen-Jin Yin; Jiong Wu; Zhi-Ming Shao
Journal:  Breast Cancer Res Treat       Date:  2009-11-27       Impact factor: 4.872

Review 9.  Laryngeal cancer: diagnosis and preoperative work-up.

Authors:  Eugene A Chu; Young J Kim
Journal:  Otolaryngol Clin North Am       Date:  2008-08       Impact factor: 3.346

10.  Gene expression profiling associated with the progression to poorly differentiated thyroid carcinomas.

Authors:  J M Pita; A Banito; B M Cavaco; V Leite
Journal:  Br J Cancer       Date:  2009-10-06       Impact factor: 7.640

View more
  7 in total

1.  Clinicopathological analysis of UHRF1 expression in medulloblastoma tissues and its regulation on tumor cell proliferation.

Authors:  Zhen-Yu Zhang; Jia-Jun Cai; Jin Hong; Kay Ka-Wai Li; Zhou Ping; Yin Wang; Ho-Keung Ng; Yu Yao; Ying Mao
Journal:  Med Oncol       Date:  2016-07-23       Impact factor: 3.064

2.  UHRF1 gene silencing inhibits cell proliferation and promotes cell apoptosis in human cervical squamous cell carcinoma CaSki cells.

Authors:  Ting-Ting Ge; Meng Yang; Zhuo Chen; Ge Lou; Tao Gu
Journal:  J Ovarian Res       Date:  2016-07-19       Impact factor: 4.234

3.  Systematic detection of positive selection in the human-pathogen interactome and lasting effects on infectious disease susceptibility.

Authors:  Erik Corona; Liuyang Wang; Dennis Ko; Chirag J Patel
Journal:  PLoS One       Date:  2018-05-25       Impact factor: 3.240

4.  UHRF1 suppression promotes cell differentiation and reduces inflammatory reaction in anaplastic thyroid cancer.

Authors:  Bi-Cheng Wang; Guo-He Lin; Bo Wang; Min Yan; Bin He; Wei Zhang; An-Kui Yang; Zi-Jie Long; Quentin Liu
Journal:  Oncotarget       Date:  2016-07-18

5.  Identification of key genes for laryngeal squamous cell carcinoma using weighted co-expression network analysis.

Authors:  Xiao-Tian Li
Journal:  Oncol Lett       Date:  2016-03-24       Impact factor: 2.967

Review 6.  The epigenetic integrator UHRF1: on the road to become a universal biomarker for cancer.

Authors:  Christian Bronner; Marc Mousli; Waseem Ashraf; Abdulkhaleg Ibrahim; Mahmoud Alhosin; Liliyana Zaayter; Khalid Ouararhni; Christophe Papin; Tanveer Ahmad; Ali Hamiche; Yves Mély
Journal:  Oncotarget       Date:  2017-04-24

Review 7.  Targeting the SET and RING-associated (SRA) domain of ubiquitin-like, PHD and ring finger-containing 1 (UHRF1) for anti-cancer drug development.

Authors:  Debasis Patnaik; Pierre-Olivier Estève; Sriharsa Pradhan
Journal:  Oncotarget       Date:  2018-05-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.